Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 24
8-K
Regulation FD Disclosure
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Regulation FD Disclosure
31 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Jan 24
424B4
Prospectus supplement with pricing info
26 Jan 24
8-K
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 Jan 24
EFFECT
Notice of effectiveness
26 Jan 24
S-1MEF
Registration of additional securities for an S-1
25 Jan 24
CORRESP
Correspondence with SEC
24 Jan 24
CORRESP
Correspondence with SEC
24 Jan 24
S-1/A
IPO registration (amended)
19 Jan 24
S-1/A
IPO registration (amended)
29 Dec 23
8-K
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
11 Dec 23
S-1/A
IPO registration (amended)
11 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
S-1
IPO registration
1 Dec 23
8-K
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
30 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Aptose Reports Results for the Third Quarter 2023
9 Nov 23
8-K
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
2 Nov 23
8-K
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
30 Oct 23
8-K
Regulation FD Disclosure
26 Oct 23
8-K
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
23 Oct 23
8-K
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
16 Oct 23
S-8
Registration of securities for employees
21 Sep 23
8-K
Aptose to Present at the Cantor Global Healthcare Conference
18 Sep 23
8-K
Entry into a Material Definitive Agreement
12 Sep 23
8-K
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
6 Sep 23
8-K
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Aptose Reports Results for the Second Quarter 2023
10 Aug 23
424B3
Prospectus supplement
6 Jul 23
EFFECT
Notice of effectiveness
3 Jul 23
S-1/A
IPO registration (amended)
28 Jun 23
CORRESP
Correspondence with SEC
28 Jun 23
8-K
Regulation FD Disclosure
26 Jun 23
UPLOAD
Letter from SEC
26 Jun 23
Latest ownership filings
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
4
Fletcher Payne
7 Feb 24
4
Rafael Bejar
7 Feb 24
4
PHILIPPE LEDRU
7 Feb 24
4
William G. Rice
7 Feb 24
4
Bernd R. Seizinger
7 Feb 24
4
ERICH PLATZER
7 Feb 24
4
Mark D. Vincent
7 Feb 24
4
Carol Gail Ashe
7 Feb 24
4
DENIS R BURGER
7 Feb 24
4
Warren Whitehead
7 Feb 24
SC 13D/A
Hanmi Pharmaceutical Co., Ltd.
5 Feb 24
4
Bernd R. Seizinger
25 Sep 23
SC 13D
Hanmi Pharmaceutical Co., Ltd.
12 Sep 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
4
Warren Whitehead
23 Jan 23
4
Mark D. Vincent
23 Jan 23
4
Bernd R. Seizinger
23 Jan 23
4
William G. Rice
23 Jan 23
4
ERICH PLATZER
23 Jan 23
4
Fletcher Payne
23 Jan 23
4
PHILIPPE LEDRU
23 Jan 23
4
DENIS R BURGER
23 Jan 23
4
Carol Gail Ashe
23 Jan 23
4
Rafael Bejar
23 Jan 23
SC 13G
Fletcher Aaron G.L.
17 Jan 23
4
William G. Rice
21 Sep 22
4
Fletcher Payne
21 Sep 22
4
Bernd R. Seizinger
16 Sep 22
3
Bernd R. Seizinger
16 Sep 22
4
William G. Rice
7 Jul 22
4
Fletcher Payne
28 Jun 22
3
Fletcher Payne
28 Jun 22
4
Caroline M Loewy
15 Jun 22
4
William G. Rice
6 Jun 22
4
PHILIPPE LEDRU
14 Apr 22
3
PHILIPPE LEDRU
14 Apr 22
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
ORBIMED CAPITAL LLC
11 Feb 22
4
Carol Gail Ashe
20 Jan 22